Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLO-AML 1: volasertib + low-dose cytarabine versus investigator's choice in relapsed/refractory AML
NL-OMON36189Phase 2Withdrawn
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of volasertib and cytarabine in acute myeloid leukemia (AML) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Complete remission rate and Overall survival. Planned start Jun 2011; status: withdrawn.
02
Drugs
volasertibcytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON36189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36189.